Patent ID: 7468352

Claim:
A method of targeting a compound to a carcinoma or fibrosarcoma cell over-expressing uPA and uPAR, the method comprising the steps of: (i) administering to the carcinoma or fibrosarcoma cell a mutant protective antigen protein comprising a uPA-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the uPA-recognized cleavage site is PGSGRSA (SEQ ID NO: 5), and wherein the mutant protective antigen is cleaved by uPA; and (ii) administering to the carcinoma or fibrosarcoma cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site; wherein the lethal factor polypeptide binds to cleaved protective antigen and is translocated into the carcinoma or fibrosarcoma cell, thereby delivering the compound to the carcinoma or fibrosarcoma cell.